Exelixis (NASDAQ:EXEL) Director Sells $4,382,251.74 in Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack Wyszomierski sold 99,574 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $4,382,251.74. Following the sale, the director directly owned 279,942 shares in the company, valued at $12,320,247.42. The trade was a 26.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Exelixis Price Performance

Shares of Exelixis stock opened at $43.63 on Monday. The company has a market capitalization of $11.33 billion, a P/E ratio of 15.75, a price-to-earnings-growth ratio of 0.98 and a beta of 0.42. The business has a 50-day moving average of $43.88 and a two-hundred day moving average of $41.25. Exelixis, Inc. has a 1 year low of $32.38 and a 1 year high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.Exelixis’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 EPS. On average, equities analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on EXEL shares. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Citigroup lowered Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price on the stock. in a research note on Monday, January 5th. Finally, Wolfe Research began coverage on shares of Exelixis in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Hold” and an average price target of $47.11.

Institutional Investors Weigh In On Exelixis

Several large investors have recently made changes to their positions in the stock. TriaGen Wealth Management LLC bought a new position in Exelixis in the 3rd quarter valued at approximately $2,024,000. BridgePort Financial Solutions LLC acquired a new position in Exelixis in the third quarter valued at $517,000. Candriam S.C.A. lifted its stake in shares of Exelixis by 18.4% in the 3rd quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock valued at $28,749,000 after purchasing an additional 108,367 shares during the period. Allianz Asset Management GmbH lifted its stake in Exelixis by 153.3% in the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock valued at $101,720,000 after buying an additional 1,490,520 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in Exelixis during the second quarter worth $321,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.